Extramedullary Progression Despite a Good Response in the Bone Marrow in Patients Treated with Thalidomide for Multiple Myeloma

References

• Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., Munshi N., Anaissie E., Wilson C., Dhodapkar M., Zeddis J., Barlogie B. Antitumor activity of thalidomide in refractory MM. New England Journal of Medicine 1999; 341: 1565–1571
   PubMed Web of Science ®Google Scholar
• Kneller A., Raanani P., Hardan I., Avigdor A., Levi I., Berkowicz M., Ben-Bassat I. Therapy with thalidomide in refractory MM patients – the revival of an old drug. British Journal of Haematology 2000; 108: 391–393
   PubMed Web of Science ®Google Scholar
• Petersen S. L., Wagner A., Gimsing P. Cerebral and meningeal MM after autologous stem cell transplantation. A case report and review of the literature. American Journal of Hematology 1999; 62: 228–233
   PubMed Web of Science ®Google Scholar
• Kato N., Kimura K., Yasukawa K., Aikawa K. Metastatic cutaneous plasmacytoma: a case report associated with IgA lambda MM and a review of the literature of metastatic cutaneous plasmacytomas associated with MM and primary cutaneous plasmacytomas. Journal of Dermatology 1999; 26: 587–594
   PubMedGoogle Scholar
• Sanal S. M., Yaylaci M., Mangold K. A., Pantazis C. G. Extensive extramedullary disease in myeloma. An uncommon variant with features of poor prognosis and dedifferentiation. Cancer 1996; 7: 1298–1302
   Google Scholar
• Foucar K., Raber M., Foucar E., Barlogie B., Sandler C. M., Alexanian R. Anaplastic myeloma with massive extramedullary involvement. Report of two cases. Cancer 1983; 51: 166–174
   PubMed Web of Science ®Google Scholar
• Zomas A., Stefanoudaki K., Fisfis M., Papadaki T., Mehta J. Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plasmacytomas. Bone Marrow Transplantation 1998; 21: 1163–1165
   PubMed Web of Science ®Google Scholar
• Rondelli D., Bandini G., Cavo M., Re F., Motta M., Senese B., Leopardi G., Stanzani M., Tura S. Discrepancy between serological complete remission and concomitant new bone lytic lesions after infusion of escalating low doses of donor lymphocytes in multiple myeloma: a case report. Bone Marrow Transplantation 1999; 24: 685–687
   PubMed Web of Science ®Google Scholar
• Juliusson G., Celsing F., Turesson I., Lenhoff S., Adriansson M., Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. British Journal of Haematology 2000; 109: 89–96
   PubMed Web of Science ®Google Scholar
• Vacca A., Ribatti D., Presta M., Minischetti M., Iurlaro M., Ria R., Albini A., Bussolino F., Dammacco F. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human MM. Blood 1999; 93: 3064–3073
   PubMed Web of Science ®Google Scholar
• D'Amato R. J., Loughnan M. S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 1994; 91: 4082–4085
   PubMed Web of Science ®Google Scholar
• Corral L. G., Haslett P. A., Muller G. W., Chen R., Wong L. M., Ocampo C. J., Patterson R. T., Stirling D. I., Kaplan G. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. Journal of Immunology 1999; 163: 380–386
   PubMed Web of Science ®Google Scholar
• Parman T., Wiley M. J., Wells P. G. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nature Medicine 1999; 5: 582–585
   PubMed Web of Science ®Google Scholar
• Geitz H., Handt S., Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996; 31: 213–221
   PubMed Web of Science ®Google Scholar
• Nogueira A. C., Neubert R., Helge H., Neubert D. Thalidomide and the immune system. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sciences 1994; 55: 77–92
   PubMed Web of Science ®Google Scholar
• Teoh G., Anderson K. C. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of MM. Hematology Oncology Clinics of North America 1997; 11: 27–42
   PubMed Web of Science ®Google Scholar
• Giralt S., O'Brien S., Weeks E., Luna M., Kantarjian H. Leukemia cutis in acute promyelocytic leukemia: report of three cases after treatment with all-trans retinoic acid. Leukaemia Lymphoma 1994; 14: 453–456
   PubMed Web of Science ®Google Scholar